ConvaTec Group PLC BOARD CHANGE (2491D)
25 June 2019 - 4:01PM
UK Regulatory
TIDMCTEC
RNS Number : 2491D
ConvaTec Group PLC
25 June 2019
BOARD CHANGE
Reading, United Kingdom (25 June 2019) - Jesper Ovesen has
advised the Board of ConvaTec Group Plc ("ConvaTec" or "the
Company") that he wishes to retire as a Non-Executive Director of
the Company on 28(th) June 2019.
Margaret Ewing, Senior Independent Director, will succeed Jesper
as Chair of the Audit and Risk Committee and Regina Benjamin will
also become a member of the Committee. Regina will also be
appointed as a member of the Remuneration Committee. These
appointments will take effect from 28(th) June.
Margaret joined the Board of ConvaTec in August 2017. She has
strong executive and non-executive experience with large listed
businesses and is currently a Non-Executive Director and Chair of
the Audit and Risk Committee of ITV plc and a Non-Executive
Director and member of the Audit and Compliance Committee of
International Airlines Group plc. She was previously CFO of BAA plc
and Trinity Mirror plc and Executive Board member of Deloitte
LLP.
Rick Anderson, Executive Chairman, commented "On behalf of the
Board I would like to thank Jesper for his valuable contribution to
ConvaTec since he became a Director in 2016.
We are very pleased that Margaret has agreed to become the Chair
of the Audit and Risk Committee, where her knowledge and experience
will be most valuable to ConvaTec."
This announcement is made in accordance with Listing Rule
9.6.11R(1).
Enquiries:
Analysts and Investors
John Crosse, VP Investor Relations +44 (0)7500 141435
Mark Reynolds, Director Investor
Relations
investorrelations@convatec.com +44 (0)7551 036625
Media
Bobby Leach, VP Group Corporate
Affairs +44 (0)7770 842226
Finsbury +44 (0)207 2513801
About ConvaTec
ConvaTec is a global medical products and technologies company
focused on therapies for the management of chronic conditions, with
leading market positions in advanced wound care, ostomy care,
continence and critical care, and infusion devices. ConvaTec's
products provide a range of clinical and economic benefits
including infection prevention, protection of at-risk skin,
improved patient outcomes and reduced total cost of care. To learn
more about ConvaTec, please visit www.convatecgroup.com where a
copy of this announcement can also be found.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
BOAFIMATMBATBML
(END) Dow Jones Newswires
June 25, 2019 02:01 ET (06:01 GMT)
Convatec (LSE:CTEC)
Historical Stock Chart
From Apr 2024 to May 2024
Convatec (LSE:CTEC)
Historical Stock Chart
From May 2023 to May 2024